End-of-life costs of medical care for advanced stage cancer patients
Abstract
Background/Aim. Cancer, one of the leading causes of mortality in the world, imposes a substantial economic burden on each society, including Serbia. The aim of this study was to evaluate the major cancer cost drivers in Serbia. Methods. A retrospective, in-depth, bottom-up analysis of two combined databases was performed in order to quantify relevant costs. End-of-life data were obtained from patients with cancer, who deceased within the first year of the established diagnose, including basic demographics, diagnosis, tumour histology, medical resource use and related costs, time and cause of death. All costs were allocated to one of the three categories of cancer health care services: primary care (included home care), hospital outpatient and hospital inpatient care. Results. Exactly 114 patients were analyzed, out of whom a high percent (48.25%) had distant metastases at the moment of establishing the diagnosis. Malignant neoplasms of respiratory and intrathoracic organs were leading causes of morbidity. The average costs per patient were significantly different according to the diagnosis, with the highest (13,114.10 EUR) and the lowest (4.00 EUR) ones observed in the breast cancer and melanoma, respectively. The greatest impact on total costs was observed concerning pharmaceuticals, with 42% of share (monoclonal antibodies amounted to 34% of all medicines and 14% of total costs), followed by oncology medical care (21%), radiation therapy and interventional radiology (11%), surgery (9%), imaging diagnostics (9%) and laboratory costs (8%). Conclusion. Cancer treatment incurs high costs, especially for end-of-life pharmaceutical expenses, ensued from medical personnel tendency to improve such patients’ quality of life in spite of nearing the end of life. Reimbursement policy on monoclonal antibodies, in particular at end-stage disease, should rely on cost-effectiveness evidence as well as documented clinical efficiency.
References
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer statistics. CA Cancer J Clin 2011; 61(2): 69−90.
World Health Organization. Global Burden of the disease 2004 update. Geneva: World Health Organization; 2008.
World Health Organization. World health statistics 2013. Geneva: World Health Organization; 2013.
Uyl-de Groot C. Economic evaluation of cancer therapies: More and better studies will lead to better choices in cancer care. Eur J Cancer 2006; 42(17): 2862−6.
Murthy RS, Lakshminarayana R. Mental health consequences of war: a brief review of research findings. World Psychiatry 2006; 5(1): 25−30.
Papathanasiou K, Gianoulis C, Tolikas A, Dovas D, Koutsos J, Frag-kedakis N, et al. Effect of depleted uranium weapons used in the Balkan war on the incidence of cervical intraepithelial neoplasia (CIN) and invasive cancer of the cervix in Greece. Clin Exp Obstet Gynecol 2005; 32(1): 58−60.
Mihajlović J, Pechlivanoglou P, Miladinov-Mikov M, Zivković S, Postma MJ. Cancer incidence and mortality in Serbia 1999-2009. BMC Cancer 2013; 13: 18.
Institute of Public Health of Serbia. Health Statistical Yearbook of Republic of Serbia 2012. Belgrade: Institute of Public Health of Serbia; 2013.
American Cancer Society. Cancer Facts and Figures 2008. Atlanta, Georgia: American Cancer Society; 2013.
Jason H. Experts debate if the cost of end-of-life cancer care is too high. HemOnc Today [cited 2009 September 10]. Availa-ble from: www.healio.com ›
Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic bur-den of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013; 14(12): 1165−74.
Jakovljevic MB. Resource allocation strategies in Southeastern European health policy. Eur J Health Econ 2013;14(2): 153−9.
Arnold RG, Kotsanos JG. Panel 3: methodological issues in con-ducting pharmacoeconomic evaluations - retrospective and claims database studies. Value Health 1999; 2(2): 82−7.
Jakovljevic M, Rankovic A, Rancic N, Jovanovic M, Ivanovic M, Gajovic O, et al. Radiology Services Costs and Utilization Patterns estimates in Southeastern Europe - A Retrospective Analysis from Serbia. Value Health Reg 2013; 2(2): 218−25.
Milijus D, Zivkovic S, Bozic Z. Cancer incidence and mortality in central Serbia. Belgrade: Institute of Public Health of Serbia “Dr Milan Jovanovic Batut”; 2012.
Leblanc TW, Abernethy AP. Defining quality, disseminating evi-dence, and enforcing guidelines for cancer treatment. Virtual Mentor 2013; 15(8): 713−7.
Institute of Public Health of Serbia. Cancer incidence and mortality in Serbia 2010. Belgrade: Institute of Public Health of Serbia; 2012.
Šipetić T. Marketing and consumption of medicinal products for human use in 2010. Belgrade: Agencija za lekove i medi-cinska sredstva Srbije; 2011. (Serbian)
Šipetić T. Marketing and consumption of medicinal products for human use in 2011. Belgrade: Agencija za lekove i medi-cinska sredstva Srbije; 2012. (Serbian)
Institute of Public Health of Serbia. Health Statistical Yearbook of Republic of Serbia 2011. Belgrade: Institute of Public Health of Serbia; 2012.
Institute of Public Health of Serbia. Health Statistical Yearbook of Republic of Serbia 2010. Belgrade: Institute of Public Health of Serbia; 2011.
Earle C, Neville B, Landrum MB, Ayanian J, Block S, Weeks J. Trends in the Aggressiveness of Cancer Care Near the End of Life. J Clin Oncol 2004; 22(2): 315−21.
Rankovic A, Rancic N, Jovanovic M, Ivanovic M, Gajovic O, Lazic Z, et al. Impact of imaging diagnostics on the budget – Are we spending too much? Vojnosanit Pregl 2013; 70(7): 709−11.
Zweifel P. The Grossman model after 40 years. Eur J Health Econ 2012; 13(6): 677−82.
Radovanovic A, Dagovic A, Jakovljevic M. Economics of cancer re-lated medical care: estimates worldwide and available domestic evidence. Arch Oncol 2011; 19(3−4): 59−63.
Autier P, Ouakrim A, Malvezzi M, Bleiberg H, Jenkins M, Boniol M, et al. Trends in colorectal cancer mortality and screening activities in European countries. Eur J Cancer 2013; 49(2 Suppl): S299.
Marsland T, Robbins G, Marks A, Cassell R, Philips Green D, King K. Reducing Cancer Costs and Improving Collaboration With Payers: A Proposal From the Florida Society of Clinical On-cology. J Oncol Pract 2010; 6(5): 265−9.
Huskamp HA, Keating NL, Malin JL, Zaslavsky AM, Weeks JC, Earle CC, et al. Discussions with physicians about hospice among patients with metastatic lung cancer. Arch Intern Med 2009; 169(10): 954−62.
Kaló Z, Landa K, Doležal T, Vokó Z. Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries. Eur J Cancer Care (Engl) 2012; 21(4): 442−9.